100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Cooperative Agreement W81XWH1420015
Award Date
9/8/14
Completion Date
7/7/18
Dollars Obligated
$3.8M
Overview
Activity
5
Transactions
5
Subawards
Similar Awards
Federal Agency
Medical Command
Awardee
Teleflex Incorporated (QTE9J4B479M6)
Federal Grant Program
12.420
Assistance Type
Cooperative Agreement
Place of Performance
Cambridge, MA 02139, USA
Update #1
Update #2
ANTI-BIOFILM TRAUMA DEVICES - PHASE TWO
Posted 9/3/14
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
3,770,903.26THE PURPOSE OF THIS MODIFICATION IS TO DE-OBLIGATE REMAINING FUNDS IN THE AMOUNT OF $798,276.74 PER THE RECIPIENTS FINAL SF-425 DATED 07 JUNE 2018. THE TOTAL AWARDED AND FUNDED AMOUNTS ARE DECREASED BY $798,276.74 FROM $4,569,180.00 TO $3,770,903.26.
($798k)
7/7/18
Not listed
THE PURPOSE OF THIS MODIFICATION IS TO (1) EXTEND THE PERIOD OF PERFORMANCE BY 9 MONTHS (THROUGH 07 JUNE 2018) AT NO ADDITIONAL COST TO THE GOVERNMENT.
$0
5/17/18
Not listed
4,569,180.00THE PURPOSE OF THIS MODIFICATION IS TO (1) EXTEND THE PERIOD OF PERFORMANCE BY 12 MONTHS (THROUGH 07 SEP 2017) AT NO ADDITIONAL COST TO THE GOVERNMENT.
$0
12/16/16
Not listed
ANTI-BIOFILM TRAUMA DEVICE - PHASE TWO
$2.5m
9/10/15
Not listed
ANTI-BIOFILM TRAUMA DEVICES - PHASE TWO
$2.1m
9/3/14